Sirolimus reduce incidencia de NMSC, en transplantados de riñón...

Does sirolimus have a protective role against nonmelanoma skin cancer?

A Brief Report in JAAD demonstrated sirolimus’ long-term efficacy in reducing nonmelanoma skin cancer (NMSC) incidence in kidney transplant recipients. The retrospective case series included 214 predominantly Caucasian, male adult kidney transplant recipients on sirolimus. NMSCs that developed two years after initiating sirolimus were attributed to sirolimus, whereas those occurring earlier were attributed to tacrolimus. 

[The ever-changing world of nevus sebaceus. Read more.]

NMSC incidences per 12 treatment months were 0.41 for sirolimus compared to 4.27 for tacrolimus, more than a 90% reduction in overall tumor burden with sirolimus. Squamous cell carcinoma (SCC) rates per year decreased from an adjusted rate of 2.97 on tacrolimus to 0.31 on sirolimus, with basal cell carcinoma incidence declining as well. The authors concluded that sirolimus treatment in kidney transplant recipients provided a significant long-term reduction in NMSC incidence compared to tacrolimus, with especially pronounced decreases in SCC.